Leukemia
Targeted therapies are effective in controlling chronic lymphocytic leukemia (CLL). New research is now looking into the impact that these agents can have on autoimmune conditions. Read More ›
A new type of immunotherapy, allogeneic cord blood–derived CAR NK-cells, could be a future option for patients with chronic lymphocytic leukemia (CLL), based on results from an early-phase clinical trial showing high response rates among patients. Read More ›
By Dana Taylor
Calquence, a new-generation targeted therapy recently approved for the treatment of CLL, has shown good results in a 3-drug combination therapy. Read More ›
By Dana Taylor
A new study using a combination of the 2 oral drugs, Copiktra and Venclexta, showed promising results for patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma. Read More ›
By Dana Taylor
Brukinsa, which was approved for use in patients with mantle-cell leukemia in late 2019, has also showed promising results in 2 recent clinical trials of patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), including patients with high-risk genetic abnormalities. Read More ›
Ibrutinib is an orally administered Bruton tyrosine kinase inhibitor used in the treatment of patients with CLL. Because ibrutinib has been prescribed in the United States for several years, researchers sought to learn how the rates of side effects in the “real world” compared with those reported in clinical trials. Read More ›
When treating patients with CLL, understanding specific details about the disease helps doctors as they choose among available treatments. CLL experts believe that conducting specific blood tests before prescribing each patient’s treatment is critical. Do all doctors who treat patients with CLL also appreciate this need for testing? Read More ›
In a large clinical trial, ibrutinib was shown to be effective in delaying disease progression in patients with early-stage, high-risk CLL who did not yet have symptoms. Researchers are now conducting clinical trials to determine the safety and efficacy of next-generation drugs and combinations in patients with early-stage, high-risk disease. Read More ›
In the era of targeted treatments for CLL, should patients with early-stage disease be placed on therapy before they experience symptoms? Doctors continue to debate this question while waiting for clinical trial data to evolve. Read More ›
Chronic lymphocytic leukemia (CLL) is a type of blood cancer. Some patients with CLL may not need treatment right away, whereas others require more urgent attention. How do cancer specialists decide when to start patients on therapy? Read More ›